🇺🇸 FDA
Pipeline program

Dovato 50 mg/300 mg film-coated tablets, Dovato 50 mg/300 mg film-coated tablets, REKAMBYS 900 mg prolonged-release suspension for injection, Vocabria 400 mg prolonged-release suspension for injection, Vocabria 600 mg prolonged-release suspension for injection

219700

Phase 3 small_molecule active

Quick answer

Dovato 50 mg/300 mg film-coated tablets, Dovato 50 mg/300 mg film-coated tablets, REKAMBYS 900 mg prolonged-release suspension for injection, Vocabria 400 mg prolonged-release suspension for injection, Vocabria 600 mg prolonged-release suspension for injection for HIV-1 infection is a Phase 3 program (small_molecule) at ViiV Healthcare BV with 1 ClinicalTrials.gov record(s).

Program details

Company
ViiV Healthcare BV
Indication
HIV-1 infection
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials